Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC / 肿瘤防治研究

ABSTRACT

Lung cancer is the leading cause of cancer-related deaths across the world, of which non-small cell lung cancer (NSCLC) accounts for 85%, and more than 50% of NSCLC patients were diagnosed with distant metastasis. The comprehensive treatment of NSCLC includes surgery, radiotherapy, chemotherapy, targeted therapy and immune checkpoint inhibitors. As one of the traditional treatment methods, radiotherapy plays an important role in the treatment of all stages of NSCLC, and its immunomodulatory effect has attracted much attention. The application of immune checkpoint inhibitors (ICIs) has significantly improved the prognosis of patients with local-advanced and advanced NSCLC, but the benefit population was limited. At present, the treatment mode of radiotherapy combined with ICIs has become the focus of research. This paper reviews the research progress of radiotherapy combined with ICIs in the treatment of NSCLC.